Raffles Medical Group (BSL) said its shareholders passed all ten resolutions at the company’s 37th annual general meeting held on Apr, 24 2026 in Singapore.

The meeting adopted the directors’ statement and audited financial statements for the year ended Dec, 31 2025, and approved a one-tier tax-exempt final dividend of 3.0 Singapore cents per ordinary share.

Investors also endorsed directors’ fees of up to 565,000 Singapore dollars and the grant of up to 1.8 million share options for FY2025.

On board matters, Executive Chairman Dr Loo Choon Yong and Non-Executive Director Mr Olivier Lim Tse Ghow were re-elected, while all proposed share-issuance mandates and the renewal of the share buy-back mandate gained support.

Shareholders backed the switch of external auditor to Ernst & Young LLP, replacing KPMG LLP, and authorised directors to fix the new auditor’s remuneration.

All resolutions received at least 88 per cent of votes cast, with most clearing the 95 per cent threshold. The meeting closed at 4:30 p.m. after a question-and-answer session covering the group’s China operations, insurance trends, and technology initiatives.